Developing, Validating AI Biomarkers to Predict Outcomes in BCG-Treated NMIBC

At the AUA 2024 Annual Meeting, Katie S. Murray, DO, of NYU Langone Urology and Bellevue Hospital, and Yair Lotan, MD, of UT Southwestern Medical Center, continue their discussion by pivoting to another of Dr. Lotan’s presented abstracts on the development and validation of generalizable, interpretable AI biomarkers to predict clinical outcomes in BCG-treated patients with non-muscle invasive bladder cancer.

View their previous comments on UGN-101 for UTUC: Longitudinal Follow Up of Multicenter Study.